Table 2 Association of PD-L1 expression according to CPS with clinico-pathologic features.
PD-L1− | PD-L1+ | p value | |
|---|---|---|---|
(CPS < 1) | (CPS ≥ 1) | ||
Number, N (%) | 90 (74) | 31 (26) | |
Age at SBA diagnosis Median (25–75th IQR) | 62 (52–71) | 56 (52–67) | 0.421 |
Sex, N (%) | |||
Female Male | 38 (86) 51 (67) | 6 (14) 25 (33) | 0.029 |
Etiologic group, N (%) | 0.001 | ||
CeD-SBA CrD-SBA Sporadic SBA | 22 (65) 32 (65) 36 (95) | 12 (35) 17 (35) 2 (5) | |
Site, N (%) | 0.172 | ||
Duodenum Jejunum Ileum | 8 (73) 41 (84) 41 (68) | 3 (27) 8 (16) 19 (32) | |
Stage, N (%) | 0.212 | ||
I II III IV | 8 (73) 39 (71) 30 (73) 11 (100) | 3 (27) 16 (29) 11 (27) 0 (0) | |
Histotype, N (%) | 0.011 | ||
Glandular Medullary Diffuse Mixed Solid | 49 (75) 2 (22) 12 (86) 21 (81) 6 (86) | 16 (25) 7 (78) 2 (14) 5 (19) 1 (14) | |
PD-1+ intratumoural cells/HPF Median (25–75th IQR) | 1.1 (0.1–5.5) | 7.2 (2.8–28.5) | <0.001 |
PD-1+ peritumoural cells/HPF Median (25–75th IQR) | 1.9 (0.4–7.8) | 13.8 (5.3–29.3) | <0.001 |
PD-1+ total cells/HPF Median (25–75th IQR) | 2.8 (1.0–16.2) | 23.8 (8.0–64.3) | <0.001 |
CD3+ TILs/HPF Median (25–75th IQR) | 7.0 (2.1–24.2) | 21.3 (15.1–75.2) | <0.001 |
CD8+ TILs/HPF Median (25–75th IQR) | 5.2 (1.0–19.3) | 52.5 (10.7–93.0) | 0.008 |
MSI status, N (%) | 0.013 | ||
Non-MSI MSI-H | 67 (82) 23 (59) | 15 (18) 16 (41) | |
CDX2 expression, N (%) | 1.000 | ||
Negative Positive | 29 (76) 60 (74) | 9 (24) 21 (26) | |
L-FABP expression, N (%) | 0.036 | ||
Negative Positive | 59 (69) 30 (88) | 27 (31) 4 (12) |
